https://clarivate.com/drugs-to-watch/drugs-to-watch-listing/rsvpref/
RSVpreF | Clarivate
clarivate
https://www.infectiousdiseaseadvisor.com/news/nirsevimab-vs-maternal-rsvpref-vaccination-infant-hospitalization/
Nirsevimab Outperforms Maternal RSVpreF Vaccination for Infant RSV Prevention - Infectious Disease...
Jun 17, 2026 - Nirsevimab immunization at birth is associated with a lower risk for RSV-related LRTI hospitalization in infants compared with maternal vaccination.
nirsevimabmaternalvaccination